about
n-butylidenephthalide protects against dopaminergic neuron degeneration and α-synuclein accumulation in Caenorhabditis elegans models of Parkinson's diseaseKnockdown of Hsc70-5/mortalin induces loss of synaptic mitochondria in a Drosophila Parkinson's disease modelMany Faces of Parkinson's Disease: Non-Motor Symptoms of Parkinson's DiseaseDysarthria in individuals with Parkinson's disease: a protocol for a binational, cross-sectional, case-controlled study in French and European Portuguese (FraLusoPark).Presynaptic dopaminergic terminal imaging and non-motor symptoms assessment of Parkinson's disease: evidence for dopaminergic basis?Factors predicting the instant effect of motor function after subthalamic nucleus deep brain stimulation in Parkinson's disease.NMR Metabolomics Analysis of Parkinson's DiseaseBase excision repair in physiology and pathology of the central nervous systemRING finger protein 11 (RNF11) modulates susceptibility to 6-OHDA-induced nigral degeneration and behavioral deficits through NF-κB signaling in dopaminergic cells.Rotenone-induced energy stress decompensated in ventral mesocerebrum is associated with Parkinsonism progression in ratsIntegrated safety of levodopa-carbidopa intestinal gel from prospective clinical trials.Research on the premotor symptoms of Parkinson's disease: clinical and etiological implications.Astragalus Polysaccharide Suppresses 6-Hydroxydopamine-Induced Neurotoxicity in Caenorhabditis elegans.Consensus on the Definition of Advanced Parkinson's Disease: A Neurologists-Based Delphi Study (CEPA Study).MicroRNAs and neurodegeneration: role and impact.Interleukin-1β and tumor necrosis factor-α: reliable targets for protective therapies in Parkinson's Disease?Prevalence, Duration and Severity of Parkinson's Disease in Germany: A Combined Meta-Analysis from Literature Data and Outpatient Samples.The influence of depression, level of functioning in everyday life, and illness acceptance on quality of life in patients with Parkinson's disease: a preliminary study.The role and structure of the multidisciplinary team in the management of advanced Parkinson's disease with a focus on the use of levodopa-carbidopa intestinal gel.Speech and Voice Response to a Levodopa Challenge in Late-Stage Parkinson's Disease.Ellagic acid improves hyperalgesia and cognitive deficiency in 6-hydroxidopamine induced rat model of Parkinson's disease.Effect of Levodopa-carbidopa Intestinal Gel on Non-motor Symptoms in Patients with Advanced Parkinson's Disease.Exercise-Induced Neuroprotection of the Nigrostriatal Dopamine System in Parkinson's Disease.Systematic evaluation of levodopa-carbidopa intestinal gel patient-responder characteristics.Advanced Parkinson's or "complex phase" Parkinson's disease? Re-evaluation is needed.The association between HSD3B7 gene variant and Parkinson's disease in ethnic Chinese.Validation of a simple screening tool for early diagnosis of advanced Parkinson’s disease in daily practice: the CDEPA questionnaire.Treatment of advanced Parkinson's disease.East Indian sandalwood ( L.) oil confers neuroprotection and geroprotection in activating SKN-1/Nrf2 signaling pathway
P2860
Q27334018-745DE71D-E7AC-4C86-B732-A2D1CFF43288Q27339390-3226DB58-42CC-4023-A359-224CB2D2FD88Q28081355-68219FC4-23C6-4B7F-A311-AC17A785BA08Q30368449-C046FCBE-F275-4413-876E-2F4B9AE1F15AQ33731267-02935458-456D-4516-AE38-716E285114A2Q33750089-A44B2FF0-F764-4BD5-8BC1-68BD2F6C4687Q35734379-80E90558-C33A-438B-A141-DA710383098AQ36538373-3536584F-CA8D-4B4C-9F32-A308C48B2DBCQ36773965-F7CD6C63-C5B4-426E-89C6-DD0CFFBBCF6BQ37108659-A6659375-6418-4599-AC8B-D8A4C84467A2Q37340428-FBD2EDFC-B01F-41AE-B0BB-2BADF9E19F24Q37374203-71E4C17A-A9A1-4A6E-AC61-89E044EF4EB8Q37418770-B6E8A203-C84B-494F-B9EC-9A0425AC1FECQ37625315-A165443C-A4A4-44F4-AD89-64C28552C4E2Q38048423-3A2701BA-7C1F-4156-9DE4-C0615E4C7232Q38103856-EA08EAE5-8F29-4744-B71C-1EB084E64905Q38659841-1CAE156E-909B-48D7-B821-03C94B43A469Q38868216-24A40493-16B4-4562-A19B-541E5961AFA5Q39099746-7AD39402-03F1-4CE1-9D2E-7858FDBE8C17Q41526736-0A5AC04A-FCB1-4D71-91C7-326B04300690Q41949030-802E63A3-8EE9-4D8E-8D07-B53690D9F42CQ47120831-AAD3EB26-1CF8-4079-8122-6DAB85A99260Q47121220-8EDE415D-E750-491C-9BAD-2034A3F5F324Q48128791-4C572B93-4F6A-450F-92A2-96A87946F3A3Q50108912-2216D57B-261E-4FEF-8D2C-B8DD2CF9FD03Q54941173-BE57F984-7415-4641-AB7F-7D10CFE102DFQ55434756-BB22A3ED-A93F-4A7D-B9DE-122957368F3BQ55645561-4263647A-671F-4E6B-B8E5-77B934BEBC36Q57484781-3C884405-0780-4254-8EE7-7C8F392BF37F
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Late-stage Parkinson disease.
@en
type
label
Late-stage Parkinson disease.
@en
prefLabel
Late-stage Parkinson disease.
@en
P1476
Late-stage Parkinson disease
@en
P2093
Joaquim J Ferreira
Miguel Coelho
P2888
P304
P356
10.1038/NRNEUROL.2012.126
P407
P577
2012-07-10T00:00:00Z
P6179
1017283620